Immutep’s experimental drug targeting LAG-3 has failed to demonstrate efficacy in a Phase 3 clinical trial for lung cancer. The trial results, announced on...
Stoke Therapeutics announced that its request for an expedited submission of a treatment for severe epilepsy has been postponed by the Food and Drug...